Almac
NCCN Calls ctDNA Emerging Colon Cancer Prognostic Marker, Does Not Back Use Outside Clinical Trials
The panel noted limited data on whether recurrence risk scores from ctDNA testing or multigene assays predict chemotherapy benefit among colon cancer patients.
The new tests, once developed, will be used for selecting patients who might best benefit from therapies for kidney disease, nonalcoholic steatohepatitis, and respiratory disease.
Almac, AstraZeneca Strike CDx Development Pact
Almac will develop companion diagnostic for use with AstraZeneca pharmaceuticals in a range of therapeutic areas.
Experts See Negatives, Positives in Proposed Post-Brexit UK IVD Regulations
While the guidance was welcome after years of uncertainty, regulatory experts say it does not provide enough detail for IVD manufacturers.
The lack of a ready infrastructure has some manufacturers spooked about a regulatory bottleneck as the date for compliance draws closer.